People
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
He’ll make a return to his former role at SV Health Investors as a Venture Partner.
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Several new reports, two by the U.S. CDC, describe just how severely COVID-19 has affected mortality figures in the U.S., and around the world, as well as ripple effects that extended to other forms of death.
John Martin, the chief executive officer who turned Gilead Sciences into a powerhouse company with treatments for hepatitis and HIV, died. He was 70 years old. A cause of death has not been announced.
Michael T. Nally became the latest Merck executive to join Flagship Pioneering, taking the reins of its machine learning protein therapy company Generate Biomedicines.
Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.
The company’s overarching aim is to edit and equip cells with molecular tools, through CRISPR, to eliminate certain cancers.
PRESS RELEASES